国际泌尿系统杂志
國際泌尿繫統雜誌
국제비뇨계통잡지
INTERNATIONAL JOURNAL OF UROLOGY AND NEPHROLOGY
2013年
6期
733-736
,共4页
糖尿病肾病
糖尿病腎病
당뇨병신병
Diabetic%Nephropathies
目的 探讨缬沙坦联合阿托伐他汀治疗早期糖尿病肾病(Diabetic nephropathy,DN)的临床疗效及安全性.方法 本院收治的87例早期DN患者随机分为对照组45例和试验组42例.对照组给予缬沙坦80mg/d口服,试验组在对照组的基础上给予阿托伐他汀20mg/d口服.治疗16周后,比较两组患者血清肌酐(Scr)、血清丙二醛(MDA)、C反应蛋白(CRP)、尿蛋白排泄率(UAER)及肾小球滤过率(GFR)等各项临床指标情况及不良反应有无差别.结果 81例患者完成既定治疗方案并获随访,治疗后两组患者血清肌Ser、MDA、CRP及UAER较治疗前均明显下降(P＜0.05)；但试验组下降更为显著(P＜0.05)；治疗后两组患者GFR无明显变化(P＞0.05)；两组患者血清CRP下降水平与UAER下降水平呈正相关(rspearson=0.61,P＜0.05).两组患者治疗期间不良反应发生率无明显差别(P＞0.05).结论 缬沙坦联合阿托伐他汀治疗早期DN的临床疗效均优于单用缬沙坦,且联合应用不增加患者不良反应发生风险.
目的 探討纈沙坦聯閤阿託伐他汀治療早期糖尿病腎病(Diabetic nephropathy,DN)的臨床療效及安全性.方法 本院收治的87例早期DN患者隨機分為對照組45例和試驗組42例.對照組給予纈沙坦80mg/d口服,試驗組在對照組的基礎上給予阿託伐他汀20mg/d口服.治療16週後,比較兩組患者血清肌酐(Scr)、血清丙二醛(MDA)、C反應蛋白(CRP)、尿蛋白排洩率(UAER)及腎小毬濾過率(GFR)等各項臨床指標情況及不良反應有無差彆.結果 81例患者完成既定治療方案併穫隨訪,治療後兩組患者血清肌Ser、MDA、CRP及UAER較治療前均明顯下降(P＜0.05)；但試驗組下降更為顯著(P＜0.05)；治療後兩組患者GFR無明顯變化(P＞0.05)；兩組患者血清CRP下降水平與UAER下降水平呈正相關(rspearson=0.61,P＜0.05).兩組患者治療期間不良反應髮生率無明顯差彆(P＞0.05).結論 纈沙坦聯閤阿託伐他汀治療早期DN的臨床療效均優于單用纈沙坦,且聯閤應用不增加患者不良反應髮生風險.
목적 탐토힐사탄연합아탁벌타정치료조기당뇨병신병(Diabetic nephropathy,DN)적림상료효급안전성.방법 본원수치적87례조기DN환자수궤분위대조조45례화시험조42례.대조조급여힐사탄80mg/d구복,시험조재대조조적기출상급여아탁벌타정20mg/d구복.치료16주후,비교량조환자혈청기항(Scr)、혈청병이철(MDA)、C반응단백(CRP)、뇨단백배설솔(UAER)급신소구려과솔(GFR)등각항림상지표정황급불량반응유무차별.결과 81례환자완성기정치료방안병획수방,치료후량조환자혈청기Ser、MDA、CRP급UAER교치료전균명현하강(P＜0.05)；단시험조하강경위현저(P＜0.05)；치료후량조환자GFR무명현변화(P＞0.05)；량조환자혈청CRP하강수평여UAER하강수평정정상관(rspearson=0.61,P＜0.05).량조환자치료기간불량반응발생솔무명현차별(P＞0.05).결론 힐사탄연합아탁벌타정치료조기DN적림상료효균우우단용힐사탄,차연합응용불증가환자불량반응발생풍험.
Objectives To evaluate the clinical efficacy and side effects of valsartan combined with atorvastatin on patients with diabetic nephropathy.Methods 87 diabetic nephropathy patients admitted to our hospital were recruited and divided into control group (n =45) and treatment group (n =42) by randomized random number tablea.Patients in control group were given valsartan 80mg/d.Patients in the treatment group were give valsartan 80mg/d plus atorvastatin 20mg/d.The serum Scr,MDA,CRP,UAER and GRF was compared between the two groups after 4-month treatment.Results 81 subjects completed the trial and follow-up.The serum Scr,MDA,CRP and UAER were improve in both control and treatment groups(P ＜0.05).No statistical difference of side effect between the two goups was observed(P ＜0.05).Significant positive correlation between CRP decrease and UAER decrease was foundafter treatment(rspearson =0.61,P ＜ 0.05).Conclusions More clinical efficacy was found in the valsartan combined with atorvastatin regimen group compared to control group,without increase the side effects.
